Monitoring the level of serum paraoxonase 1 activity in liver transplantation patients

Hepatobiliary and Pancreatic Diseases International

Volumn 4, Issue 2, 2005, Pages 178-181

  Xu, Gen Yun ^a   Lv, Guo Cai ^a   Chen, Yu ^a   Hua, Yong Chuan ^a   Zhu, Shen Mei ^a   Yang, Yi Da ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

glutamyltransferase; Alanine transaminase; Aspartate transaminase; Cholinesterase; Liver transplantation; Paraoxonase 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ASPARTATE AMINOTRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; GRAFT SURVIVAL; HUMAN; LIVER FAILURE; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; PATIENT MONITORING; PORTAL VEIN; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; REFERENCE VALUE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LIVER FAILURE; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PERIOPERATIVE CARE; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 20344403055     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mackness B, Durrington PN, Mackness MI. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 2002;13:357-362.
2. Gocmen AY, Gumuslu S, Semiz E. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease. Clin Cardiol 2004;27:426-430.
3. Leviev I, Poirier O, Nicaud V, Evans A, Kee F, Arveiler D, et al. High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis 2002;161:463-467.
4. Lawlor DA, Day IN, Gaunt TR, Hinks LJ, Briggs PJ, Kiessling M, et al. The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC. Genet 2004;5:17.
5. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 2004;4:211-217.
6. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 2002;32:259-264.
7. Murata M, Maruyama T, Suzuki Y, Saruta T, Ikeda Y. Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Diabet Med 2004;21:837-844.
8. Dantoine TF, Debord J, Merle L, Lacroix-Ramiandrisoa H, Bourzeix L, Charmes JP. Paraoxonase 1 Activity: A New Vascular Marker of Dementia? Ann N Y Acad Sci 2002;977:96-101.
9. Helbecque N, Cottel D, Codron V, Berr C, Amouyel P. Paraoxonase 1 gene polymorphisms and dementia in humans. Neurosci Lett 2004;358-41-44.
10. Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2002;252:63-67.
11. Sozmen EY, Mackness B, Sozmen B, Durrington P, Girgin FK, Aslan L, et al. Effect of organophosphate intoxication on human serum paraoxonase. Hum Exp Toxicol 2002;21:247-252.
12. Worth J. Paraoxonase polymorphisms and organophosphates. Lancet 2002;360:802-803.
13. Paragh G, Asztalos L, Seres I, Balogh Z, Locsey L, Karpati I, et al. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 1999;83:126-131.
14. Hasselwander O, Savage DA, McMaster D, Loughrey CM, McNamee PT, Middleton D, et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999;56:289-298.
15. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998;9:2082-2088.
16. Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L, et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002; 48:261-268.
17. Zheng SS, Liang T, Cheng J, Huang D, Zhang M, Wang Y. Two cases of combined liver-kidney transplantation. Chin Med J (Engl. ) 2000;113:1104-1107.
18. Zheng SS, Huang D, Wu J, Wang W, Shen Y, Zhang M, et al. Orthotopic liver transplantation with no veno-venous bypass. Chin J Surg (Chin) 2002;40:326-328.
19. Wu J, Zheng SS. Liver transplantation in China: problems and their solutions. Hepatobiliary Pancreat Dis Int 2004,3:170-174.
20. James RW, Deakin SP. The importance of high-density lipo-proteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004;37:1986-1994.